SRR23303763
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- PROTEIN_SECRETION+0.520
- OXIDATIVE_PHOSPHORYLATION+0.410
- CHOLESTEROL_HOMEOSTASIS+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- PI3K_AKT_MTOR_SIGNALING+0.330
- MTORC1_SIGNALING+0.320
- ADIPOGENESIS+0.290
- GLYCOLYSIS+0.290
- FATTY_ACID_METABOLISM+0.270
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.480
- PANCREAS_BETA_CELLS-0.400
- ALLOGRAFT_REJECTION-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- INFLAMMATORY_RESPONSE-0.300
- TNFA_SIGNALING_VIA_NFKB-0.270
- KRAS_SIGNALING_DN-0.260
- MYC_TARGETS_V2-0.260
- MYOGENESIS-0.260
- SPERMATOGENESIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_CZ3NA7KV | Supratentorial Ependymoma | — | 0.765 |
| 2 | R177 | — | — | 0.751 |
| 3 | BS_G3RJTBZD | high-grade glioma | — | 0.743 |
| 4 | BS_4NWHYH53 | Supratentorial Ependymoma | — | 0.733 |
| 5 | R386 | — | — | 0.731 |
| 6 | F2FCC449-3487-474C-82A6-8F2ED71E41BC | — | — | 0.730 |
| 7 | 82956 | EPN | Supratentorial EPN | 0.729 |
| 8 | BS_CZ3ER8DY | Supratentorial Ependymoma | — | 0.726 |
| 9 | TCGA-DK-AA77-01A-11R-A39I-07 | — | — | 0.724 |
| 10 | DRR168564 | — | — | 0.722 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.520 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |